c-MET inhibitor PHA-665752, Purity ≥98%

Synonym: 477575-56-7; c-MET inhibitor; PHA665752

MDL: MFCD07772270
CAS Number: 477575-56-7
Compound CID: 10461815

Product Size

5 mg; 10 mg; 50 mg; 100 mg

Price

Datasheet

MSDS

Properties

Description

PHA-665752, soluble in DMSO and insoluble in ethanol and water, inhibits the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF), interfering with pathways leading to cell growth and metastasis. It targets Flk1, RON, Aurora A2, c-Abl, c-Met, c-Src, CDK2, EGFR, FGFR1, IGF-1R, and MK2.

Molecular Weight

641.6

Molecular Formula

C₃₂H₃₄Cl₂N₄O₄S

Targets

Flk-1: 200 nM; RON: 68 nM; AuroraA2: >10 μM; c-Abl: 1.4 nM; c-Met: 9 nM; c-Src: 6 nM; CDK2: >10 μM; EGFR: 3.8 μM; FGFR1: 3 μM; IGF-1R: >10 μM; MK2: >10 μM

Form

Lyophilized powder

Purity

Solubility

DMSO: 124 mg/mL (193.26 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Applications

PHA-665752 targets c-MET, facilitating research into therapeutic strategies that disrupt MET signaling in cancer.